Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib for Prevention of Oxaliplatin-Induced Neuropathy
NCT04164069Phase 1Completed
- Start
- Sep 2020
- Primary completion
- Jun 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dasatinib. Primary endpoints: Recommended Phase 2 Dose at 14 days and Incidence of Adverse Events. Started Sep 2020; status: completed.
02
Drugs
dasatinib
Beyond the preview
Go deeper on NCT04164069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04164069.